Cardiovascular · Topic 14 of 48

Heart Transplant Recipient

Cardiovascular · advanced heart failure

Heart Transplant Recipient

A denervated heart: fast at rest, deaf to atropine, silent when ischemic — and every immunosuppressant interaction can mean toxicity or rejection.

Key numbers

Denervated heart: resting rate 90–130resting HR 90–130

Infection timeline: nosocomial, opportunistic, then communityopportunistic: months 1–6

01 · Look forDenervated heart: resting rate 90–130

Surgical denervation leaves a resting heart rate of about 90–130 bpm with a blunted, delayed rate response to exercise or stress; cardiac output rises mainly through Frank–Starling stroke volume rather than rate.

02 · AvoidCYP3A4 drugs swing tacrolimus and cyclosporine levels

Calcineurin inhibitors are CYP3A4 substrates: azoles, macrolides, diltiazem/verapamil, grapefruit and nirmatrelvir/ritonavir raise levels (toxicity); rifampin, carbamazepine, phenytoin and nafcillin lower them (rejection). Check every new drug.

03 · Watch forAllograft vasculopathy presents without angina

Cardiac allograft vasculopathy (diffuse intimal coronary narrowing) is the main long-term killer; because the heart is denervated it rarely causes angina and presents as heart failure, arrhythmia or sudden death.

Diagnosis & monitoring

Work-up

Rejection is often silent: endomyocardial biopsy confirms must knowMost rejection is asymptomatic, so recipients have scheduled surveillance; endomyocardial biopsy is the gold standard. New heart failure, atrial arrhythmia or a falling ejection fraction means rejection until proven otherwise — call the transplant center.

Calcineurin inhibitor toxicity: kidney, potassium, magnesiumTacrolimus and cyclosporine cause nephrotoxicity, hyperkalemia, hypomagnesemia, hypertension, tremor and headache (tacrolimus also post-transplant diabetes); dose by 12-hour trough levels and avoid NSAIDs and unnecessary contrast.

Acute rejection peaks in the first monthAcute rejection peaks at 1 month, falls over the next 5 months and levels off by 1 year; about 15% of adult recipients have a rejection episode in the first year.

Management

Orders

Atropine fails: give isoproterenol, epinephrine or pace must knowVagally mediated drugs fail in the transplanted heart: atropine and glycopyrrolate do not raise the rate. Treat symptomatic bradycardia with direct-acting agents (isoproterenol, epinephrine) or pacing.

Maintenance: tacrolimus, mycophenolate, corticosteroidsStandard maintenance immunosuppression is tacrolimus plus mycophenolate plus corticosteroids, often after induction with an IL-2 receptor antibody; mTOR inhibitors (sirolimus, everolimus) may replace part of the regimen and slow allograft vasculopathy.

Treat significant rejection with pulse methylprednisoloneModerate or severe rejection on biopsy, or mild rejection with graft dysfunction, is treated with pulse glucocorticoids (methylprednisolone) plus antithymocyte globulin as needed; mild rejection without dysfunction needs no treatment.

Prophylaxis: TMP-SMX and valganciclovirGive TMP-SMX for Pneumocystis (it also covers Toxoplasma, Listeria and Nocardia) and valganciclovir CMV prophylaxis tailored to donor/recipient serostatus, monitoring for leukopenia; treat CMV disease with IV ganciclovir.

Low-dose statin for every recipientGive every heart transplant recipient a statin regardless of cholesterol to reduce allograft vasculopathy, starting low (pravastatin, rosuvastatin or atorvastatin) because calcineurin inhibitors raise myopathy risk.

Red flags & don'ts

Avoid harm

Avoid or reduce adenosine avoidDenervated hearts are supersensitive to adenosine, which can cause prolonged high-grade AV block or asystole; avoid it or use only a reduced dose with pacing available. Digoxin also fails to slow AV conduction.

No live vaccines after transplant avoidLive vaccines (MMR, live varicella, BCG) are contraindicated after transplant; inactivated vaccines (influenza, COVID-19, pneumococcal, recombinant zoster) restart about 3–6 months post-transplant and are deferred during rejection treatment.

Skin cancer and lymphoproliferative disease rise complicationMalignancy is a leading cause of death 5–10 years after transplant: skin cancer is most common (yearly skin checks, sun protection) and post-transplant lymphoproliferative disorder is a major late killer.

The rules

Know these

Infection timeline: nosocomial, opportunistic, then communityMonth 1: surgical and nosocomial infections. Months 1–6: opportunistic infections and reactivation (CMV, Pneumocystis, Listeria, Nocardia, Toxoplasma). After 6 months: mostly community pathogens, unless immunosuppression is intensified for rejection.

More detail

Reference

Show 8 reference facts

After a biatrial anastomosis the ECG may show two P waves: the donor sinus node drives the QRS, while the recipient's remnant atrial activity does not cross the suture line.

Allograft vasculopathy affects about 30% of recipients within 5 years (about 50% by 10 years); it is screened with stress testing or coronary angiography with or without intravascular ultrasound.

Survival is about 90% at 1 year and 80% at 5 years; early deaths are from rejection or infection, later deaths from allograft vasculopathy or lymphoproliferative disease.

For post-transplant hypertension, dihydropyridine CCBs (amlodipine, nifedipine) or ACE inhibitors/ARBs are used; diltiazem and verapamil raise calcineurin inhibitor levels, and ACE inhibitors/ARBs add hyperkalemia and renal risk.

Early post-transplant bradycardia (18–27%) usually resolves within 3 weeks; a permanent pacemaker (about 1.5%) is considered if it persists beyond 3 weeks.

Noninvasive rejection surveillance adds gene-expression profiling, donor-derived cell-free DNA and donor-specific antibodies to biopsy and echocardiography.

Mycophenolate is teratogenic (REMS program) and must be avoided in pregnancy; transplant recipients planning pregnancy are co-managed with the transplant center.

Because the heart rate responds slowly, rehabilitation includes prolonged warm-up and cool-down; some sympathetic reinnervation can improve exercise response over time.

Pearl

No nerves, no vagus, no angina: atropine does nothing and allograft vasculopathy arrives as heart failure or sudden death, not chest pain.

Sources · Merck Manual Professional — Heart Transplantation · Care of Adult Heart Transplant Recipients by the Primary Care Provider: A Practical Roadmap. J Clin Med 2025;14:1346 (PMC11856219; summarizes 2023 ISHLT guidelines) · Perioperative care of heart transplant recipients undergoing non-cardiac surgery. Ann Card Anaesth 2021 (PMC8253024) · Management of Infection in Patients With Kidney Transplant (solid-organ infection timeline after Fishman). 2018 (PMC7152491) · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).